Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Convergence is going virtual. Join the brightest minds in regulatory online to gain the latest knowledge in the field in an all-virtual experience with workshops, one-on-one expert sessions, and networking communities.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
The last exam window of 2020 is currently open. Register by 8 October to take the RAC exam this autumn.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 03 September 2013 | By Ansis Helmanis,
Legislation has been introduced in India that would establish a new Central Drugs Authority (CDA) with overarching power to regulated drugs, devices and cosmetics.
The Drugs and Cosmetics (Amendment) Bill of 2013 was introduced on 30 August 2013 in the Rajya Sabha (Upper House of Indian Parliament) by Health and Family Welfare Minister Ghulam Nabi Azad and would replace the Drugs and Cosmetics Act of 1940.
The Central Drugs Authority would be composed of 19 members, headed by the Secretary of the Ministry of Health and Family Welfare (MHFW). It would establish regulations and norms for effective functioning of central and state drug licensing authorities and periodically assess their functioning. It would also have the authority to review, suspend or cancel any permission or license for drugs and cosmetics manufacturing.
The bill establishes centralized licensing for 17 categories of critical drugs, and includes separate chapters with regulatory frameworks governing medical devices, product exports and clinical trials, including provision for compensation for deaths or injury of a trial subjects. Penalties for violations are also set forth in the bill.
Read all Breaking News at RegLink
Regulatory Focus newsletters
All the biggest regulatory news and happenings.